{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"description":"Toxic death, defined as death predominantly attributable to treatment-related causes.","groups":[{"description":"Patients will receive 6 cycles of Induction chemotherapy consisting of carboplatin and etoposide (Cycles 1, 3, and 5) alternating with ifosfamide and etoposide (Cycles 2, 4, and 6). The entire length of Induction is 18 weeks unless delay occurs due to myelosuppression or unanticipated toxicity. Each cycle of Induction will begin when ANC \\> 750/L and platelets \\> 75,000/L and when off filgrastim (G-CSF) for at least 48 hours. Following the Induction phase (weeks 0-18) those patient in CR will undergo radiation therapy.\n\ncarboplatin: Given IV\n\netoposide: Given IV\n\nifosfamide: Given IV\n\nthiotepa: Given IV\n\nadjuvant therapy\n\nconventional surgery\n\nneoadjuvant therapy\n\nperipheral blood stem cell transplantation\n\nradiation therapy: craniospinal irradiation","id":"OG000","title":"Radiation Therapy (CR From Induction)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"A total of 102 eligible patients treated with induction chemotherapy were included.","reportingStatus":"POSTED","timeFrame":"During chemotherapy (up to 18 weeks)","title":"Number of Patients Experiencing Toxic Death","type":"SECONDARY","unitOfMeasure":"Participants"}